Clinical Trial
Sirolimus for Long COVID
This is an off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. This study aims to evaluate the safety and efficacy of sirolimus in adults with Long COVID. Following the initial trial, participants will be eligible to participate in an open-label extension.
Is this a virtual opportunity?
No, this is not a virtual opportunity.
What are the location requirements?
You must be located in the USA. You must be located in or near New York City, or be able to travel there, for in-person study visits at the clinic.
Will there be in-person visits? If so, how many?
Yes, there will be 5 in-person visits.
Where is the study located?
5 East 98th Street, New York, New York, USA.
What is the length of participation?
The length of participation is 6 months.
What health qualifications are there to participate?
Long COVID (required proof of COVID infection which caused Long COVID)
What kinds of tasks are associated with participation?
There will be blood draws, saliva collection, and surveys.
If I receive sirolimus in the trial, will I lose access after the trial concludes? If I receive a placebo, will I ever be able to try sirolimus?
We are excited to announce an open-label extension for this trial — after the initial six-month period, both patients who received sirolimus and those who received a placebo will have the opportunity to participate in further research where a CoRE provider prescribes them sirolimus and studies their response.